| Breast
Research Program
The
Breast Research Program at Loyola University Health
System is a major program of the Cardinal Bernardin
Cancer Center and the Loyola University Chicago
Stritch School of Medicine Oncology
Institute. Clinical research physicians and
basic scientists work in close collaboration to
develop innovative treatments and diagnostic techniques
for breast cancer patients as well as preventive
strategies for patients at risk of developing
breast cancer.
“Translational research” defines the
program’s philosophy. Translational research
converts cellular, genetic and molecular discoveries
into actual tools for patient care. These tools
may encompass disease treatment, diagnosis and
prevention. In contrast to traditional research,
which focuses on proving a hypothesis or treating
a diagnosis, translational research connects the
laboratory and clinic. The result is improved
patient care.
Loyola’s
Breast Preclinical
Research Program works directly with the Breast
Clinical Research Program to provide promising
clinical research studies for our patients, as
well as offer a broad menu of national and international
clinical trials. Together, these programs have
produced initiatives that are at the national
and international forefront of breast cancer research
both in the laboratory and in the clinic.
The
Breast Preclinical Research Program is focused
on basic science research of breast cancer and
takes place in laboratories ("research bench").
Directed by Lucio Miele, MD, PhD, the program
includes several research teams that are exploring
novel breast cancer medications, therapeutic targets,
diagnostic biomarkers and sophisticated investigations
of the molecular basis for rational and targeted
therapies.
The
Breast Clinical Research Program involves a team
of medical oncologists, surgical oncologists,
radiation oncologists, nurse researchers and other
professionals, directed by Kathy S. Albain, MD.
This research is conducted in clinics or in the
hospital setting (clinical research or "bedside").
Dr. Albain is internationally recognized for her
role in developing new treatment paradigms for
breast cancer and for her cancer survivorship
studies.
In
the case of Loyola's Breast Research Program,
the bedside-to-bench-to-bedside collaborations
are critical for a meaningful and successful research
program.
Related
Links
Clinical
trials
|
